-
公开(公告)号：US10590111B2
公开(公告)日：2020-03-17
申请号：US15534838
申请日：2015-12-11
发明人： Jirong Peng , Michael John Costanzo , Michael Nicholas Greco , Michael Alan Green , Victoria Lynn Wilde , Don Zhang
IPC分类号： C07D403/04 , C07D403/14 , C07D401/14 , C07D471/04 , A61K31/506 , A61K45/06
摘要： This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
-
公开(公告)号：US20200216421A1
公开(公告)日：2020-07-09
申请号：US16819539
申请日：2020-03-16
发明人： Jirong Peng , Michael John Costanzo , Michael Nicholas Greco , Michael Alan Green , Victoria Lynn Wilde , Don Zhang
IPC分类号： C07D403/04 , A61K45/06 , C07D471/04 , C07D403/14 , C07D401/14 , A61K31/506
摘要： This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
-
公开(公告)号：US11414401B2
公开(公告)日：2022-08-16
申请号：US16819539
申请日：2020-03-16
发明人： Jirong Peng , Michael John Costanzo , Michael Nicholas Greco , Michael Alan Green , Victoria Lynn Wilde , Don Zhang
IPC分类号： C07D403/04 , C07D401/14 , C07D471/04 , C07D403/14 , A61K31/506 , A61K45/06 , A61P35/00 , A61P43/00
摘要： This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
-
公开(公告)号：US20170362203A1
公开(公告)日：2017-12-21
申请号：US15534838
申请日：2015-12-11
发明人： Jirong Peng , Michael John Costanzo , Michael Nicholas Greco , Michael Alan Green , Victoria Lynn Wilde , Don Zhang
IPC分类号： C07D403/04 , C07D401/14 , A61K31/506 , A61K45/06 , C07D471/04 , C07D403/14
摘要： This application discloses novel substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, prodrugs, and compositions thereof, which are useful for the treatment or prevention of diseases or medical conditions mediated by epidermal growth factor receptors (EGFRs), including but not limited to a variety of cancers.
-
公开(公告)号：US20210139459A1
公开(公告)日：2021-05-13
申请号：US16965376
申请日：2019-01-29
申请人： Beta Pharma, Inc.
IPC分类号： C07D401/14 , A61K45/06
摘要： 2-Aminopyrimidine-substituted 2H-indazole compounds of formula (I), where R1 is hydrogen, and their prodrugs, where R1 is a metabolizable group under physiological conditions, as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.
-
公开(公告)号：US11352341B2
公开(公告)日：2022-06-07
申请号：US16965376
申请日：2019-01-29
申请人： Beta Pharma, Inc.
IPC分类号： C07D401/14 , A61K45/06
摘要： 2-Aminopyrimidine-substituted 2H-indazole compounds of formula (I), where R1 is hydrogen, and their prodrugs, where R1 is a metabolizable group under physiological conditions, as cyclin-dependent kinase (CDK) and cell-proliferation inhibitors, and therapeutic uses and methods of preparation thereof, are disclosed. These compounds, and pharmaceutically acceptable salts, solvates, prodrugs, and pharmaceutical compositions thereof, are useful for treating diseases and disorders associated with activity of cyclin-dependent kinases, in particular CDK4/6, including but not limited to various cancers and inflammation-related diseases or conditions.
-
公开(公告)号：US11180478B2
公开(公告)日：2021-11-23
申请号：US16622119
申请日：2018-06-15
申请人： Beta Pharma, Inc.
发明人： Michael Nicholas Greco , Michael John Costanzo , Michael Alan Green , Jirong Peng , Victoria Lynn Wilde , Don Zhang
IPC分类号： A61K31/506 , C07D403/04 , A61K47/02 , A61K47/10 , A61K47/38
摘要： A pharmaceutical formulation of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (compound 1), in particular methanesulfonic acid salt thereof, and methods of using the pharmaceutical formulation for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers, are disclosed.
-
公开(公告)号：US20240140948A1
公开(公告)日：2024-05-02
申请号：US18547052
申请日：2022-03-09
申请人： BETA PHARMA, INC.
发明人： Don Zhang , Jirong Peng , Michael John Costanzo , Michael Alan Green , Michael Nicholas Greco , Stephen Bolgunas
IPC分类号： C07D471/04 , C07D519/00
CPC分类号： C07D471/04 , C07D519/00
摘要： The present invention is directed to inhibitors of Kirsten Rat sarcoma virus (KRAS), and more particularly to compounds of Formula I as well as compositions comprising Formula I and methods of using the compound of Formula I for the treatment or prevention of a disease, disorder, or medical condition mediated through KRAS, especially the KRAS mutant G12C.
-
9.发明申请公开(公告)号：US20220347177A1
公开(公告)日：2022-11-03
申请号：US17641868
申请日：2020-09-23
申请人： BETA PHARMA, INC.
IPC分类号： A61K31/506 , A61P35/00 , A61P11/00
摘要： Methods of treating EGFR mutant-related cancers with a combination of an EGFR inhibitor of Formula (I) and the CDK4/6 inhibitor of Formula (II) and use of combinations of these compounds in the manufacture of medicaments for the treatment of EGFR mutant-related cancers are disclosed:
-
公开(公告)号：US11052086B2
公开(公告)日：2021-07-06
申请号：US16300949
申请日：2017-05-11
申请人： Beta Pharma, Inc.
发明人： Michael Nicholas Greco , Michael John Costanzo , Michael Alan Green , Jirong Peng , Victoria Lynn Wilde , Don Zhang
IPC分类号： A61K31/506 , A61P35/04
摘要： Methods of using substituted 2-anilinopyrimidine derivatives, and pharmaceutically acceptable salts, solvates, or compositions, for the treatment of brain cancers, in particular EGFR-mediated metastatic brain cancer, are disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.025 秒)
